3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
5
Breast Neoplasms
5
Ureteral Neoplasms
4
Neoplasms
4
Urethral Neoplasms
2
Recurrence
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Cisplatin
6
pembrolizumab
5
fludarabine
5
Nivolumab
5
Cyclophosphamide
5
aldesleukin
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ifosfamide
4
Radiotherapy
3
Ipilimumab
3
fludarabine phosphate
2
entinostat
2
cabozantinib
2
avelumab
2
aflibercept
2
Specimen Handling
2
CTLA-4 Antigen
2
Adoptive Transfer
2
vinflunine
1
toripalimab
1
rocakinogene sifuplasmid
1
ripretinib
1
oncogene protein E7, Human papillomavirus type 16
1
niraparib
1
nimotuzumab
1
lenvatinib
1
enfortumab vedotin
1
durvalumab
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Penile Neoplasms
×
vinflunine
×
Clear all
NCT02057913
2020-07-23
VinCaP
Institute of Cancer Research, United Kingdom
Phase 2
Completed
22 enrolled